ABCC2 and lung cancer: Although there are inconsistencies in the literature, previous reports also support a link between genetic variations in the ABCC1 and ABCC2 genes, altered irinotecan pharmacokinetics and clinical outcomes in colon and lung cancer patients (Rosner et al., 2008; Innocenti et al., 2009; Akiyama et al., 2012; Li et al., 2016).